Current toxicological aspects on drug and chemical transport and metabolism across the human placental barrier

Expert Opinion on Drug Metabolism and Toxicology

Volumn 8, Issue 10, 2012, Pages 1263-1275

  Giaginis, Constantinos ^a   Theocharis, Stamatios ^b   Tsantili Kakoulidou, Anna ^c  

^a UNIVERSITY OF THE AEGEAN   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

Active transport; Computer aided technologies; Fetotoxicity; Metabolism; Passive diffusion; Placental barrier

Indexed keywords

AGMATINE; ANTHRACYCLINE; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIRETROVIRUS AGENT; BENZO[A]PYRENE; CALCIUM CHANNEL BLOCKING AGENT; CIMETIDINE; CLONIDINE; COCAINE; CYCLOSPORIN A; DOXORUBICIN; GLIBENCLAMIDE; HYDROCORTISONE; MEPYRAMINE; METHOTREXATE; MEVINOLIN; MITOXANTRONE; NITROFURANTOIN; NONSTEROID ANTIINFLAMMATORY AGENT; OFLOXACIN; PHENAZONE; PRAZOSIN; PROCAINAMIDE; RITONAVIR; SAQUINAVIR; UNINDEXED DRUG; VERAPAMIL; VINBLASTINE; XENOBIOTIC AGENT;

ACTIVE TRANSPORT; ANATOMY; BLOOD PLACENTA BARRIER; CLINICAL ASSESSMENT; DIFFUSION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG TRANSPORT; FETOTOXICITY; FETUS DEVELOPMENT; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATERNAL HYPERTENSION; NONHUMAN; PASSIVE DIFFUSION; PHYSICAL CHEMISTRY; PLACENTA FUNCTION; PLACENTAL TRANSFER; PRENATAL DRUG EXPOSURE; REVIEW; SYNCYTIOTROPHOBLAST; TOXICOLOGY;

ANIMALS; BIOLOGICAL TRANSPORT; DRUG DESIGN; FEMALE; FETAL DEVELOPMENT; HUMANS; MATERNAL-FETAL EXCHANGE; PERFUSION; PHARMACEUTICAL PREPARATIONS; PLACENTA; PREGNANCY; RISK ASSESSMENT;

EID: 84866502152     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2012.699041     Document Type: Review

References (87)

1. Kaufmann P, Frank HG. Placental development. In: Polin RA, Fox WW, Abman SH, editors. Fetal and neonatal physiology. Saunders; London: 2006. p. 85-97
2. Evain-Brion D, Malassine A. Human placenta as an endocrine organ. Growth Horm IGF Res 2003;13:S34-7 (Pubitemid 37161655)
3. Cross JC. Placental function in development and disease. Reprod Fertil Dev 2006;18:71-6
4. Collins TF. History and evolution of reproductive and developmental toxicology guidelines. Curr Pharm Des 2006;12:1449-65 (Pubitemid 44082105)
5. Botting J. The history of thalidomide. Drug News Perspect 2002;15:604-11 (Pubitemid 36025547)
6. Younglai EV, Wu YJ, Foster WG. Reproductive toxicology of environmental toxicants: Emerging issues and concerns. Curr Pharm Des 2007;13:3005-19 (Pubitemid 350130967)
7. Myllynen P, Pasanen M, Vahakangas K. The fate and effects of xenobiotics in human placenta. Expert Opin Drug Metab Toxicol 2007;3:331-46 (Pubitemid 47316028)
8. Burton GJ, Jauniaux E, Charnock-Jones DS. Human early placental development: Potential roles of the endometrial glands. Placenta 2007;28:S64-9 (Pubitemid 46508697)
9. Fowden AL, Forhead AJ. Endocrine regulation of feto-placental growth. Horm Res 2009;72:257-65
10. Aplin JD, Jones CJ, Harris LK. Adhesion molecules in human trophoblast - a review. I. Villous trophoblast. Placenta 2009;30:293-8
11. Osol G, Mandala M. Maternal uterine vascular remodeling during pregnancy. Physiology (Bethesda) 2009;24:58-71
12. Hewitt M, Ellison CM, Enoch SJ, et al. Integrating (Q)SAR models, expert systems and read-across approaches for the prediction of developmental toxicity. Reprod Toxicol 2010;30:147-60
13. Myren M, Mose T, Mathiesen L, Knudsen LE. The human placenta-an alternative for studying foetal exposure. Toxicol in Vitro 2007;21:1332-40 (Pubitemid 350026248)
14. Merchant SJ, Crocker IP, Baker PN, et al. Matrix metalloproteinase release from placental explants of pregnancies complicated by intrauterine growth restriction. J Soc Gynecol Investig 2004;11:97-103 (Pubitemid 38229737)
15. Hawfield A, Freedman BI. Pre-eclampsia: The pivotal role of the placenta in its pathophysiology and markers for early detection. Ther Adv Cardiovasc Dis 2009;3:65-73
16. Carter AM. Animal models of human placentation - a review. Placenta 2007;28:S41-7 (Pubitemid 46508694)
17. Georgiades P, Ferguson-Smith AC, Burton GJ. Comparative developmental anatomy of the murine and human definitive placentae. Placenta 2002;23:3-19 (Pubitemid 41110436)
18. Vahakangas K, Myllynen P. Experimental methods to study human transplacental exposure to genotoxic agents. Mutat Res 2006;608:129-35 (Pubitemid 44311606)
19. Audus KL. Controlling drug delivery across the placenta. Eur J Pharm Sci 1999;8:161-5 (Pubitemid 29324643)
20. Holcberg G, Tsadkin-Tamir M, Sapir O, et al. New aspects in placental drug transfer. Isr Med Assoc J 2003;5:873-6 (Pubitemid 38008109)
21. Myllynen P, Pasanen M, Pelkonen O. Human placenta: A human organ for developmental toxicology research and biomonitoring. Placenta 2005;26:361-71 (Pubitemid 40567913)
22. Bode CJ, Jin H, Rytting E, et al. In vitro models for studying trophoblast transcellular transport. Methods Mol Med 2006;122:225-39
23. Hemmings DG, Lowen B, Sherburne R, et al. Villous trophoblasts cultured on semi-permeable membranes form an effective barrier to the passage of high and low molecular weight particles. Placenta 2001;22:70-9 (Pubitemid 32124099)
24. King A, Thomas L, Bischof P. Cell culture models of trophoblast II: Trophoblast cell lines - A workshop report. Placenta 2000;21:S113-19
25. Wadsack C, Hrzenjak A, Hammer A, et al. Trophoblast-like human choriocarcinoma cells serve as a suitable in vitro model for selective cholesteryl ester uptake from high density lipoproteins. Eur J Biochem 2003;270:451-62 (Pubitemid 36177312)
26. Sullivan MH. Endocrine cell lines from the placenta. Mol Cell Endocrinol 2004;228:103-19 (Pubitemid 39482522)
27. Sastry BV. Techniques to study human placental transport. Adv Drug Deliv Rev 1999;38:17-39 (Pubitemid 29216951)
28. Syme MR, Paxton JW, Keelan JA. Drug transfer and metabolism by the human placenta. Clin Pharmacokinet 2004;43:487-514 (Pubitemid 38858303)
29. Di Santo S, Malek A, Sager R, et al. Trophoblast viability in perfused term placental tissue and explant cultures limited to 7-24 hours. Placenta 2003;24:882-94 (Pubitemid 37184817)
30. Schneider H, Panigel M, Dancis J. Transfer across the perfused human placenta of antipyrine, sodium and leucine. Am J Obstet Gynecol 1972;114:822-8
31. Miller RK, Wier PJ, D' Gregorio RP, et al. Human dual placental perfusions-criteria for toxicity evaluations. Methods Toxicol 1993;3B:246-59
32. Gedeon C, Koren G. Designing pregnancy centered medications: Drugs which do not cross the human placenta. Placenta 2006;27:861-8 (Pubitemid 43905924)
33. Ala-Kokko TI, Myllynen P, Vahakangas K. Ex vivo perfusion of the human placental cotyledon: Implications for anesthetic pharmacology. Int J Obstet Anesth 2000;9:26-38 (Pubitemid 30093365)
34. Akbaraly JP, Leng JJ, Bozler G, Seydel JK. Quantitative relationship between tranplacental transfer physicochemical properties of a series of heterogenous drugs. Proceeding of the Fifth European Symposium on Quantitative Structure-Activity Relationships, Federal Republic of Germany; Bad Segeberg, 1984. VCH, Verlagsgeselischaft, Weinheim: 1985. p. 313-17
35. Malkia A, Murtomaki L, Urtti A, Kontturi K. Drug permeation in biomembranes: In vitro and in silico prediction and influence of physicochemical properties. Eur J Pharm Sci 2004;23:13-47 (Pubitemid 39485996)
36. Pacifici GM. Transfer of antivirals across the human placenta. Early Hum Dev 2005;81:647-54 (Pubitemid 41058726)
37. Pacifici GM. Placental transfer of antibiotics administered to the mother: A review. Int J Clin Pharmacol Ther 2006;44:57-63 (Pubitemid 43230587)
38. Elliott BD, Schenker S, Langer O, et al. Comparative placental transport of oral hypoglycemic agents in humans: A model of human placental drug transfer. Am J Obstet Gynecol 1994;171:653-60 (Pubitemid 24312344)
39. Giaginis C, Tsantili-Kakoulidou A, Theocharis S. Assessing drug transport across the human placental barrier: From in vivo and in vitro measurements to the ex vivo perfusion method and in silico techniques. Curr Pharm Biotechnol 2011;12:804-13
40. Hewitt M, Madden JC, Rowe PH, Cronin MT. Structure-based modelling in reproductive toxicology: (Q)SARs for the placental barrier. SAR QSAR Environ Res 2007;18:57-76
41. Giaginis C, Zira A, Theocharis S, Tsantili-Kakoulidou A. Application of quantitative structure-activity relationships for modeling drug and chemical transport across the human placenta barrier: A multivariate data analysis approach. J Appl Toxicol 2009;29:724-33
42. Giaginis C, Zira A, Theocharis S, Tsantili-Kakoulidou A. Simple physicochemical properties as effective filters for risk estimation of drug transport across the human placental barrier. Rev Clin Pharmacol Pharmacokin (Int Edition) 2008;22:146-8 (Pubitemid 351831235)
43. Klieger C, Pollex E, Kazmin A, Koren G. Hypoglycemics: Pharmacokinetic considerations during pregnancy. Ther Drug Monit 2009;31:533-41
44. Gulati A, Gerk PM. Role of placental ATP-binding cassette (ABC) transporters in antiretroviral therapy during pregnancy. J Pharm Sci 2009;98:2317-35
45. Anderson GD. Pregnancy-induced changes in pharmacokinetics: A mechanistic-based approach. Clin Pharmacokinet 2005;44:989-1008 (Pubitemid 41356388)
46. Ganapathy V, Prasad PD. Role of transporters in placental transfer of drugs. Toxicol Appl Pharmacol 2005;207:381-7
47. Evseenko DA, Paxton JW, Keelan JA. Active transport across the human placenta: Impact on drug efficacy and toxicity. Exp Opin Drug Metab Toxicol 2006;2:51-69 (Pubitemid 46100728)
48. Vahakangas K, Myllynen P. Drug transporters in the human blood-placental barrier. Br J Pharmacol 2009;158:665-78
49. Tanabe M, Ieiri I, Nagata N, et al. Expression of P-glycoprotein in human placenta: Relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 2001;297:1137-43 (Pubitemid 32472514)
50. Ganapathy V, Prasad PD, Ganapathy ME, Leibach FH. Placental drug transporters relevant to drug distribution across the maternal-fetal interface. J Pharmacol Exp Ther 2000;294:413-20 (Pubitemid 30490810)
51. Carbonne B, Jannet D, Touboul C, et al. Nicardipine treatment of hypertension during pregnancy. Obstetr Gynecol 1993;81:908-14 (Pubitemid 23168731)
52. Wang EJ, Casciano CN, Clement RP, Johnson WW. In vitro flow cytometry method to quantitatively assess inhibitors of P-glycoprotein. Drug Metab Dispos 2000;28:522-8 (Pubitemid 30238510)
53. Tsatsaris V, Papatsonis D, Goffinet F, et al. Tocolysis with nifedipine or beta-adrenergic agonists: A meta-analysis. Obstetr Gynecol 2001;97:840-7 (Pubitemid 32406194)
54. Ceccaldi PF, Gavard L, Mandelbrot L, et al. Functional role of p-glycoprotein and binding protein effect on the placental transfer of lopinavir/ritonavir in the ex vivo human perfusion model. Obstet Gynecol Int 2009;2009:726593
55. Pascolo L, Fernetti C, Pirulli D, et al. Effects of maturation on RNA transcription and protein expression of four MRP genes in human placenta and in BeWo cells. Biochem Biophys Res Commun 2003;303:259-65 (Pubitemid 36338234)
56. Deeley RG, Cole SP. Substrate recognition and transport by multidrug resistance protein 1 (ABCC1). FEBS Lett 2006;580:1103-11 (Pubitemid 43185290)
57. Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003;22:7340-58 (Pubitemid 37487163)
58. Rizwan AN, Burckhardt G. Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles. Pharm Res 2007;24:450-70 (Pubitemid 46295167)
59. Peltekova VD, Wintle RF, Rubin LA, et al. Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat Genet 2004;36:471-5 (Pubitemid 38620030)
60. Ohashi R, Tamai I, Yabuuchi H, et al. Na+-dependent carnitine transport by organic cation transporter (OCTN2): Its pharmacological and toxicological relevance. J Pharmacol Exp Ther 1999;291:778-84 (Pubitemid 29503553)
61. Vahakangas K, Raunio H, Pasanen M, et al. Comparison of the formation of benzo[a]pyrene diolepoxide-DNA adducts in vitro by rat and human microsomes: Evidence for the involvement of P-450IA1 and P-450IA2. J Biochem Toxicol 1989;4:79-86
62. Hakkola J, Pelkonen O, Pasanen M, Raunio H. Xenobiotic-metabolizing cytochrome P450 enzymes in the human feto-placental unit: Role in intrauterine toxicity. Crit Rev Toxicol 1998;28:35-72 (Pubitemid 28100181)
63. Pasanen M. The expression and regulation of drug metabolism in human placenta. Adv Drug Deliv Rev 1999;38:81-97 (Pubitemid 29216955)
64. Miller RK, Genbacev O, Turner MA, et al. Human placental explants in culture: Approaches and assessments. Placenta 2005;26:439-48 (Pubitemid 40796572)
65. Partanen HA, El-Nezami HS, Leppanen JM, et al. Aflatoxin B1 transfer and metabolism in human placenta. Toxicol Sci 2010;113:216-25
66. Storvik M, Huuskonen P, Kyllonen T, et al. Aflatoxin B1-a potential endocrine disruptor--up-regulates CYP19A1 in JEG-3 cells. Toxicol Lett 2011;202:161-7
67. Collier AC, Tingle MD, Paxton JW, et al. Metabolizing enzyme localization and activities in the first trimester human placenta: The effect of maternal and gestational age, smoking and alcohol consumption. Hum Reprod 2002;17:2564-72 (Pubitemid 35174105)
68. Choi SM, Yoo SD, Lee BM. Toxicological characteristics of endocrinedisrupting chemicals: Developmental toxicity, carcinogenicity, and mutagenicity. J Toxicol Environ Health B Crit Rev 2004;7:1-24 (Pubitemid 38117512)
69. Piasek M, Laskey JW, Kostial K, Blanusa M. Assessment of steroid disruption using cultures of whole ovary and/or placenta in rat and in human placental tissue. Int Arch Occup Environ Health 2002;75:S36-44 (Pubitemid 36075164)
70. Paakki P, Kirkinen P, Helin H, et al. Antepartum glucocorticoid therapy suppresses human placental xenobiotic and steroid metabolizing enzymes. Placenta 2000;21:241-6 (Pubitemid 30240791)
71. Paakki P, Stockmann H, Kantola M, et al. Maternal drug abuse and human term placental xenobiotic and steroid metabolizing enzymes in vitro. Environ Health Perspect 2000;108:141-5 (Pubitemid 30153919)
72. Pasanen M, Haaparanta T, Sundin M, et al. Immunochemical and molecular biological studies on human placental cigarette smoke-inducible cytochrome P-450-dependent monooxygenase activities. Toxicology 1990;62:175-87 (Pubitemid 20183325)
73. Pasanen M, Helin-Martikainen HL, Pelkonen O, Kirkinen P. Intrahepatic cholestasis of pregnancy impairs the activities of human placental xenobiotic and steroid metabolizing enzymes in vitro. Placenta 1997;18:37-41 (Pubitemid 27105508)
74. Carlberg CE, Moller L, Paakki P, et al. DNA adducts in human placenta as biomarkers for environmental pollution, analysed by the 32P-HPLC method. Biomarkers 2000;5:182-91 (Pubitemid 30619107)
75. Perera F, Hemminki K, Jedrychowski W, et al. In utero DNA damage from environmental pollution is associated with somatic gene mutation in newborns. Cancer Epidemiol Biomarkers Prev 2002;11:1134-7 (Pubitemid 35192673)
76. Everson RB, Randerath E, Santella RM, et al. Quantitative associations between DNA damage in human placenta and maternal smoking and birth weight. J Natl Cancer Inst 1988;80:567-76
77. Valerio LG. Computational science in drug metabolism and toxicology. Expert Opin Drug Metab Toxicol 2010;6:781-4
78. Valerio LG Jr. In silico toxicology for the pharmaceutical sciences. Toxicol Appl Pharmacol 2009;241:356-70
79. Simon-Hettich B, Rothfuss A, Steger-Hartmann T. Use of computer-assisted prediction of toxic effects of chemical substances. Toxicology 2006;224:156-62
80. Tropsha A, Golbraikh A. Predictive QSAR modeling workflow, model applicability domains, and virtual screening. Curr Pharm Des 2007;13:3494-504 (Pubitemid 350238939)
81. Cronin MTD, WorthAP, (Q)SARs for predicting effects relating to reproductive toxicity. QSAR Comb Sci 2008;27:91-100 (Pubitemid 351204937)
82. Zvinavashe E, Murk AJ, Rietjens IM. Promises and pitfalls of quantitative structure-activity relationship approaches for predicting metabolism and toxicity. Chem Res Toxicol 2008;21:2229-36
83. Madden JC, Cronin MT. Structure-based methods for the prediction of drug metabolism. Expert Opin Drug Metab Toxicol 2006;2:545-57 (Pubitemid 46118325)
84. Mekenyan OG, Dimitrov SD, Pavlov TS, Veith GD. A systematic approach to simulating metabolism in computational toxicology. I. The TIMES heuristic modelling framework. Curr Pharm Design 2004;10:1273-93 (Pubitemid 38425906)
85. Cruciani G, Carosati E, De Boeck B, et al. MetaSite: Understanding metabolism in human cytochromes from the perspective of the chemist. J Med Chem 2005;48:6970-9 (Pubitemid 41533118)
86. Khalil F, Laer S. Physiologically based pharmacokinetic modeling: Methodology, applications, and limitations with a focus on its role in pediatric drug development. J Biomed Biotechnol 2011;2011:907461
87. Sun H, Pang KS. Physiological modeling to understand the impact of enzymes and transporters on drug and metabolite data and bioavailability estimates. Pharm Res 2010;27:1237-54